Literature DB >> 30143244

Targeting FcRn to Generate Antibody-Based Therapeutics.

E Sally Ward1, Raimund J Ober2.   

Abstract

The MHC class I-related receptor FcRn serves multiple roles ranging from the regulation of levels of IgG isotype antibodies and albumin throughout the body to the delivery of antigen into antigen loading compartments in specialized antigen-presenting cells. In parallel with studies directed towards understanding FcRn at the molecular and cellular levels, there has been an enormous expansion in the development of engineering strategies involving FcRn to modulate the dynamic behavior of antibodies, antigens, and albumin. In this review article, we focus on a discussion of FcRn-targeted approaches that have resulted in the production of novel antibody-based platforms with considerable potential for use in the clinic.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  FcRn; FcRn-targeted therapeutics; antibody engineering; pharmacokinetics

Mesh:

Substances:

Year:  2018        PMID: 30143244      PMCID: PMC6169532          DOI: 10.1016/j.tips.2018.07.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  99 in total

1.  Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.

Authors:  W L Martin; A P West; L Gan; P J Bjorkman
Journal:  Mol Cell       Date:  2001-04       Impact factor: 17.970

2.  Using multifocal plane microscopy to reveal novel trafficking processes in the recycling pathway.

Authors:  Zhuo Gan; Sripad Ram; Raimund J Ober; E Sally Ward
Journal:  J Cell Sci       Date:  2013-01-23       Impact factor: 5.285

Review 3.  Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer.

Authors:  Robert Goldstein; Jane Sosabowski; Kim Vigor; Kerry Chester; Tim Meyer
Journal:  Expert Rev Anticancer Ther       Date:  2013-03       Impact factor: 4.512

4.  Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells.

Authors:  Kristi Baker; Shuo-Wang Qiao; Timothy T Kuo; Victoria G Aveson; Barbara Platzer; Jan-Terje Andersen; Inger Sandlie; Zhangguo Chen; Colin de Haar; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-31       Impact factor: 11.205

5.  Enhanced antibody half-life improves in vivo activity.

Authors:  Jonathan Zalevsky; Aaron K Chamberlain; Holly M Horton; Sher Karki; Irene W L Leung; Thomas J Sproule; Greg A Lazar; Derry C Roopenian; John R Desjarlais
Journal:  Nat Biotechnol       Date:  2010-01-17       Impact factor: 54.908

Review 6.  Cross-presentation of IgG-containing immune complexes.

Authors:  Kristi Baker; Timo Rath; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Cell Mol Life Sci       Date:  2012-07-31       Impact factor: 9.261

7.  Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.

Authors:  Yik Andy Yeung; Maya K Leabman; Jonathan S Marvin; Julia Qiu; Camellia W Adams; Samantha Lien; Melissa A Starovasnik; Henry B Lowman
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

8.  Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor.

Authors:  Devin B Tesar; Noreen E Tiangco; Pamela J Bjorkman
Journal:  Traffic       Date:  2006-09       Impact factor: 6.215

9.  Engineered monoclonal antibody with novel antigen-sweeping activity in vivo.

Authors:  Tomoyuki Igawa; Atsuhiko Maeda; Kenta Haraya; Tatsuhiko Tachibana; Yuki Iwayanagi; Futa Mimoto; Yoshinobu Higuchi; Shinya Ishii; Shigero Tamba; Naoka Hironiwa; Kozue Nagano; Tetsuya Wakabayashi; Hiroyuki Tsunoda; Kunihiro Hattori
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

10.  Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.

Authors:  Angela Schoch; Hubert Kettenberger; Olaf Mundigl; Gerhard Winter; Julia Engert; Julia Heinrich; Thomas Emrich
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

View more
  22 in total

1.  Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study.

Authors:  Yoichi Nakayama; Ryu Watanabe; Kosaku Murakami; Koichi Murata; Masao Tanaka; Hiromu Ito; Wataru Yamamoto; Kosuke Ebina; Kenichiro Hata; Yuri Hiramatsu; Masaki Katayama; Yonsu Son; Hideki Amuro; Kengo Akashi; Akira Onishi; Ryota Hara; Keiichi Yamamoto; Koichiro Ohmura; Shuichi Matsuda; Akio Morinobu; Motomu Hashimoto
Journal:  Rheumatol Int       Date:  2022-03-10       Impact factor: 2.631

Review 2.  B Cell Responses: Cell Interaction Dynamics and Decisions.

Authors:  Jason G Cyster; Christopher D C Allen
Journal:  Cell       Date:  2019-04-18       Impact factor: 41.582

Review 3.  Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway.

Authors:  Green Ahn; Steven M Banik; Carolyn R Bertozzi
Journal:  Cell Chem Biol       Date:  2021-03-25       Impact factor: 9.039

Review 4.  Targets and Antibody Formats for Immunotherapy of Neuroblastoma.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  J Clin Oncol       Date:  2020-03-13       Impact factor: 44.544

Review 5.  The Neonatal Fc Receptor (FcRn): A Misnomer?

Authors:  Michal Pyzik; Kine M K Sand; Jonathan J Hubbard; Jan Terje Andersen; Inger Sandlie; Richard S Blumberg
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

Review 6.  Pemphigus: Current and Future Therapeutic Strategies.

Authors:  Dario Didona; Roberto Maglie; Rüdiger Eming; Michael Hertl
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

Review 7.  Complement in malaria immunity and vaccines.

Authors:  Liriye Kurtovic; Michelle J Boyle; D Herbert Opi; Alexander T Kennedy; Wai-Hong Tham; Linda Reiling; Jo-Anne Chan; James G Beeson
Journal:  Immunol Rev       Date:  2019-09-26       Impact factor: 12.988

Review 8.  The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control.

Authors:  Roberta Lucchi; Jordi Bentanachs; Benjamí Oller-Salvia
Journal:  ACS Cent Sci       Date:  2021-04-26       Impact factor: 14.553

Review 9.  Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.

Authors:  Alicia M Chenoweth; Bruce D Wines; Jessica C Anania; P Mark Hogarth
Journal:  Immunol Cell Biol       Date:  2020-04-12       Impact factor: 5.126

Review 10.  Monoclonal Antibody-Based Therapies for Myasthenia Gravis.

Authors:  Sawsan Alabbad; Mohanad AlGaeed; Patricia Sikorski; Henry J Kaminski
Journal:  BioDrugs       Date:  2020-10       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.